利鲁唑在肌萎缩侧索硬化患者哪个临床阶段延长生存:剂量范围研究数据的回顾性分析
该研究利用King临床分期系统回顾分析原始利鲁唑剂量范围试验的959例肌萎缩侧索硬化患者数据,发现100 mg/日利鲁唑组在4期停留时间长于安慰剂组(HR 0.55,95%CI 0.36-0.83),而2期或3期向后续阶段或死亡的时间无差异,提示利鲁唑在疾病最后临床阶段延长生存。
要点
- 100 mg/日利鲁唑组4期停留时间长于安慰剂组(HR 0.55,95%CI 0.36-0.83)。
- 2期和3期向后续阶段或死亡的时间在利鲁唑组与安慰剂组间无显著差异。
- 作者认为该发现需前瞻性研究确认,1期治疗效应仍需分析。
核心结论
- 利鲁唑在肌萎缩侧索硬化的最后临床阶段延长生存,该发现需前瞻性研究确认,1期治疗效应仍需分析。
研究设计与样本
- 对原始利鲁唑剂量范围临床试验数据做回顾性分析,纳入1992年12月至1993年11月在比利时、法国、德国、西班牙、加拿大、美国和英国入组的959例很可能或确定的肌萎缩侧索硬化患者。
- 生存数据删失日期设为原始研究结束日期1994年12月31日,King临床分期根据修改版Norris量表、英国医学研究委员会肌力评分、El Escorial分类、肺活量和胃造瘘置入数据估计,最低分配分期为2期。
主要发现
- 入组时临床分期在各治疗组间无显著差异(p=0.22)。
- 100 mg/日利鲁唑组4期停留时间长于安慰剂组(HR 0.55,95%CI 0.36-0.83;log-rank p=0.037)。
- 合并治疗组并按入组时分期的分析显示相似结果(HR 0.638,95%CI 0.464-0.878;p=0.006)。
- 2期向后续阶段或死亡的时间在利鲁唑组与安慰剂组间无差异(p=0.83),3期亦无差异(p=0.88)。
临床怎么用
- 作者认为发生获益的肌萎缩侧索硬化临床阶段对开始治疗前咨询患者很重要。
- 作者认为未来肌萎缩侧索硬化临床试验应使用分期评估生存获益发生的阶段,类似方法可用于其他神经退行性疾病。
局限性
- 该发现需前瞻性研究确认。
- 1期治疗效应仍需分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS) and, at a dose of 100 mg, was associated with a 35% reduction in mortality in a clinical trial. A key question is whether the survival benefit occurs at an early stage of disease, late stage, or is spread throughout the course of the disease. To address this question, we used the King's clinical staging system to do a retrospective analysis of data from the original dose-ranging clinical trial of riluzole. METHODS: In the original dose-ranging trial, patients were enrolled between December, 1992, and November, 1993, in Belgium, France, Germany, Spain, Canada, the USA, and the UK if they had probable or definite ALS as defined by the El Escorial criteria. The censor date for the riluzole survival data was set as the original study end date of Dec 31, 1994. For this analysis, King's clinical ALS stage was estimated from the electronic case record data of the modified Norris scale, UK Medical Research Council score for muscle strength, El Escorial category, vital capacity, and gastrostomy insertion data. The lowest allocated stage was 2 because the original trial only included patients with probable or definite ALS. We used a χ2 test to assess the independence of stage at trial enrolment and treatment group, Kaplan-Meier product limit distribution to test the transition from each stage to subsequent stages, and Cox regression to confirm an effect of treatment group on time in stage, controlling for covariates. We did sensitivity analyses by combining treatment groups, using alternative strategies to stage, stratifying by stage at trial enrolment, and using multistate outcome analysis of treatments (MOAT). FINDINGS: We analysed the case records of all 959 participants from the original dose-ranging trial, 237 assigned to 50 mg/day riluzole, 236 to 100 mg/day, 244 to 200 mg/day, and 242 to daily placebo. Clinical stage at enrolment did not significantly differ between treatment groups (p=0·22). Time in stage 4 was longer for patients receiving 100 mg/day riluzole than for those receiving placebo (hazard ratio [HR] 0·55, 95% CI 0·36-0·83; log-rank p=0·037). Combining treatment groups and stratifying by stage at enrolment showed a similar result (HR 0·638, 95% CI 0·464-0·878; p=0·006), as did analysis with MOAT where the mean number of days spent in stage 4 was numerically higher for patients given riluzole at higher doses compared with patients receiving placebo. Time from stages 2 or 3 to subsequent stages or death did not differ between riluzole treatment groups and placebo (p=0·83 for stage 2 and 0·88 for stage 3). INTERPRETATION: We showed that riluzole prolongs survival in the last clinical stage of ALS; this finding needs to be confirmed in a prospective study, and treatment effects at stage 1 still need to be analysed. The ALS stage at which benefit occurs is important for counselling of patients before starting treatment. Staging should be used in future ALS clinical trials to assess the stage at which survival benefit occurs, and a similar approach could be used for other neurodegenerative diseases. FUNDING: NIHR Maudsley Biomedical Research Centre, The European Union Joint Programme on Neurodegeneration, and the King's Summer Undergraduate Studentship.
引用
- Fang T, Al Khleifat A, Meurgey JH, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018. PMID: 29525492. doi:10.1016/S1474-4422(18)30054-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。